



Mersana Therapeutics Announces Poster and Presentation at the American Association for Cancer Research Annual Meeting 2019

March 25, 2019

CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present preclinical data from Mersana's proprietary, novel Dolasynthen platform and its modular Synthemmer scaffold at the 2019 American Association for Cancer Research (AACR) Annual Meeting being held from March 29 – April 3, 2019 in Atlanta, GA.

Details of the poster session and presentation are as follows:

Poster Title: "An Antibody-Drug Conjugate Carrying a Microtubule Inhibitor and a DNA Alkylator Exerts Both Mechanisms of Action on Tumor Cells"

Date: March 31, 2019

Time: 1:00 PM – 5 PM E.T.

Location: Section 9

Session: PO.ET01.01 - Antibody-drug Conjugates: New Agents and Technologies

Abstract: #232 / 23

Presentation Title: "Dolasynthen - A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform"

Date: April 1, 2019

Time: 3:05 PM – 3:20 PM E.T.

Location: Room B401 - Georgia World CC

Session: MS.ET01.01 - Novel Therapeutic Agents and Screening Approaches

Abstract: #2687

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms and its modular Synthemmer scaffold to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's lead product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC adenocarcinoma, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

Contact:

Investor & Media Contact

Sarah Carmody, 617-844-8577

scarmody@mersana.com



Source: Mersana Therapeutics, Inc.